Next Phase Newsletter

A Western Europe based venture capital firm provides university spin-offs as well as other promising start-up companies with capital, coaching and networks. The firm is an advisor to multiple funds, and is investing in a variety of technological industries; about 50% of the portfolio is in the life science sector. The firm makes allocations from $500,000 to $10M over the life of the investment, and in the life science sector allocations are typically over $5m. The firm primarily invests in companies based in Europe or with ties to Europe. Allocations to US, Canada and Israel are possible.

The firm invests in the biotech and medtech sectors and is opportunistic within these sectors regarding indication area and technology. The firm prefers to invest in early-stage companies, with assets ranging from preclinical to mid-stage clinical trials (Phase II for therapeutics).

The firm seeks highly qualified, ambitious management teams, and is typically an activist investor that takes a seat on a portfolio company’s board.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture arm of a large company is a stage-agnostic investor, and makes investments from Series B to growth stage. Investments are therefore varied in size relative to the type of investment; initial allocations are most often from $5-10 million with the possibility of follow-on investments up to $20 million. The firm is open to opportunities worldwide but has previously focused on investing in the USA, Canada and Europe.

The firm focuses on four areas of innovation in healthcare; pharma services, data and analytics, digital supply chain, consumer health, value based care. The firm is focused on financial returns in addition to how the firm can potentially contribute value to the company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An angel investing firm founded in 2017 is based in San Francisco with easy access to Silicon Valley. Since January 2017, the firm has invested in several life sciences companies and continues to actively

invest. Typical size of investment ranges from $25-75K, and the firm provides strategic advisory and resources in addition to capital. The firm is open to considering investments from all across the globe.

The angel group is most interested in consumer-facing medtech and digital health technologies, especially those with a user experience design element that enables patient empowerment. The firm is primarily open to investing in Class 1 and 2 medical devices (e.g. SaMD and 510K) and generally avoids Class 3/PMA programs. The firm’s current portfolio includes a monitoring system for pediatric asthma, a wearable for measuring continuous blood pressure, a patient journey support service for cancer patients, an extended duration urinary catheter, etc. In general, the firm does not invest in physician tools, surgical devices or biopharma therapeutics with the occasional exception of areas in which the firm principal has expertise, including respiratory drug delivery, COPD, and diabetes.

The angel group seeks to work with motivated and passionate management teams developing novel products in the life sciences space. Most importantly, the firm seeks to work with companies where the firm could be of most value and becomes actively involved in helping their portfolio companies grow. That said, the firm does not necessarily seek board representation. An important additional discriminating factor is the perceived integrity and humility of the key executives.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

The fund is looking for innovative and transformative therapeutics focused on preclinical drug development. The firm is a subsidiary of a foundation, which it can leverage the team at the foundation for venture and investment services, as well as operational support. The firm’s goal is to shepherd promising drug candidates through the riskiest, early stages of development. The firm will help its portfolio companies with experienced management, scientists, consultants, and investors.

The fund is interested in early-stage bioscience and therapeutics area including Autoimmune diseases and Immunology, Biofuels, Cancer, Cardiovascular Research, Glycobiology and Carbohydrates, Infectious Disease and Microbiology, Natural Products for Health, Vision Research. The firm is interested in companies in in development to pre-clinical stage.

The fund has no management team requirements and will work with entrepreneurs of all experience levels coming from academia or industry, and has no restriction on the geographic location of companies or technologies.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

The Corporate Venture Fund is a $50 million venture fund established by the parent company, an insurance company. The focus of the initiative is to develop a portfolio of investments that, as a whole, focus on improving the health care market, enhance the core business of the company and generate revenue. These strategic investments are expected to be integrated into the company as part of its overall long-term strategy. The firm prefers to syndicate with a strong lead investor in a financing round and expects to make 5 – 7 new investments of $0.5-2 million in the coming year. The firm considers opportunities across the US and around the world with preference given to companies in the middle of the country.

The fund is interested in digital health technologies and care delivery models that can improve healthcare. The firm prefers products with prototype and customer traction.

The fund would like to be a strategic partner, as a payer, for startups. The firm prefers early stage teams backed by experienced management, supported by reputable early stage VC and/or angel groups that have a history of follow-on investments in Series A and B.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

A newly established venture capital firm founded in 2020 and is based in Barcelona, Spain. The firm is currently raising its first fund targeting €30M, and expects to close in mid to late 2021 and become fully operative. The firm is actively seeking investment opportunities and performing due diligence on companies they identify as a fit with the firm. The firm’s focus is in Seed to Series A financings and initial size of investment will be around €500K, and can invest up to €2.5M over the life of investment. The firm is open to USA-based opportunities but will focus on those based in Europe, Israel, and Spain where the firm is based.

The firm is exclusively interested in companies in the longevity space. In this regard, the firm is most interested in digital technologies including AI, robotics, data analytics, etc. Traditional therapeutics or devices do not fall within their investment priority, as the firm prefers to seek opportunities that leverage digital technologies to deliver novel therapeutic solutions (i.e. digital therapeutics). The firm is open to very early-stage, pre-revenue technologies and are open to university spin-offs/tech transfers.

The firm is backed by co-founders who have entrepreneurial backgrounds and can be a hands-on investor, assisting with company creation and other support as needed. When investing in companies that are not in geographical proximity to the firm, the firm prefers to co-invest alongside larger VC firms.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

A Venture Capital firm based in CA invests in companies in Consumer, Enterprise, as well as Life Science & Digital Health. For companies in the life sciences, the firm generally invests in Series seed/A/B rounds, committing between $1-10M in capital. The firm is willing to invest in both the US and China, and will consider companies in pre-clinical and clinical development.

Within the life sciences, the firm is willing to invest in therapeutics, diagnostics, medtech, digital health and R&D services. For therapeutics, the firm will consider traditional therapeutics that are first-in-class, either a novel target or novel therapeutic, but is agnostic to indication. For diagnostics, medtech, digital health and R&D services, the firm focuses on AI-based technologies. Previous investments include AI-based drug discovery platforms, pathology screening, diagnostic services and care management platforms.

The firm looks for companies with a strong management team, large market opportunity and a disruptive technology. When investing, the firm is willing lead or co-invest, and will occasionally take a board seat after investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.